权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanisms of Anesthetic Effects on Tachykinin Induced Airway Tone

麻醉对速激肽诱导气道张力的影响机制

基本信息

批准号：
7987289
负责人：
CHARLES W EMALA
金额：
$ 34.92万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-04-01 至 2015-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7987289
关键词：
3-aminobutyric acid Address Aerosols Affect Agonist American Anesthetics Anti-Cholinergics Anti-Inflammatory Agents Anti-inflammatory Asthma Attenuated Bathing Binding Biological Assay Cavia Cell membrane Cell surface Cells Chemosensitization Childhood Chloride Ion Chlorides Chronic Data Disease Effectiveness Electrophysiology (science)Epithelial Cells Epithelium Frequencies Funding GABA Receptor GABA transporter Goals High Pressure Liquid Chromatography Human Immunoblotting Immunohistochemistry In Vitro Inflammatory Knockout Mice Laboratories Ligands Measures Mediating Mediation Membrane Molecular Mus Muscle Tonus Muscle relaxation phase Nerve Neurons Organ Phosphotransferases Prevalence Propofol Receptor Activation Regulation Relative (related person)Relaxation Research Reverse Transcriptase Polymerase Chain Reaction Role Severities Small Interfering RNA Smooth Muscle Smooth Muscle Myocytes Source Specificity Symptoms Synapses System Tachykinin Therapeutic Tissues Trachea airway epithelium airway obstruction constriction gamma-Aminobutyric Acid improved in vivo inhibitor/antagonist laser capture microdissection methacholine novel pandemic disease paracrine prevent receptor respiratory smooth muscle transport inhibitor uptake

项目摘要

DESCRIPTION (provided by applicant): Asthma is a chronic inflammatory disease of the airways whose global prevalence has taken on pandemic proportions. Although research has made great strides in elucidating the underlying mechanisms involved in asthma, in recent decades relatively few new additions have been made to the pharmacological armamentarium for this disease. Our laboratory has made several novel discoveries: (1) that 3-aminobutyric acid subtype A (GABAA) GABAA receptors are expressed on airway smooth muscle cells, (2) that an endogenous GABAergic ligand-receptor system exists in the airway, (3) that activation of endogenous airway smooth muscle GABAA receptors potentiates relaxation, (4) that GABA (endogenously present in the airway) functions to modulate airway smooth muscle tone, (5) that systemic administration of a GABAA receptor agonist administered in vivo attenuates agonist-induced airway constriction and that (6) part of propofol's broncho-relaxant effect is mediated by GABAA receptors on airway smooth muscle. Since pharmacologic specificity of ligands/agonists directed at the GABAA receptor is dictated by GABAA subunit composition, selective targeting of certain subunits restricted to a given tissue hold promise for improved therapy. Therefore, our goal is to elucidate the importance of airway smooth muscle GABAA receptor subunit composition on the modulation of airway smooth muscle tone. We previously demonstrated that human airway smooth muscle expresses a limited, yet highly conserved repertoire of GABAA receptor subunits (including 14, 15, 23, 32 and 42. This limited repertoire of subunits is advantageous, as it may allow for highly selective targeting of GABAA ) receptors expressed on airway smooth muscle. Exciting preliminary data generated for this proposal support the central hypothesis that airway epithelium is an important cellular source for airway GABA. It is released from epithelial cells via kinase- regulated GABA transporters (GAT2 and GAT4/BGT-1) to act upon 14- and/or 15 containing GABAA receptors on airway smooth muscle cells to facilitate relaxation. These findings offer a radical new therapy, a translational therapeutic approach and a novel paradigm for paracrine interactions between airway epithelium and smooth muscle for relaxing airway constriction. PUBLIC HEALTH RELEVANCE: The central hypotheses to be addressed by the studies are that airway epithelium is a cellular source for airway GABA that is released from epithelial cells via kinase-regulated GABA transporters (GAT2 and GAT4/BGT-1). This released GABA can then act upon 14- and/or 15 containing GABAA receptors on airway smooth muscle cells to facilitate relaxation. We plan to identify novel 14 or 15 subunit-selective agonists that can be delivered to airways by aerosol to facilitate airway relaxation. These findings offer a radical new therapy, a translational therapeutic approach and a novel paradigm for paracrine interactions between airway epithelium and smooth muscle for relaxing airway constriction.

描述(申请人提供)：哮喘是一种慢性呼吸道炎症性疾病，其全球流行率已达到大流行的比例。虽然研究在阐明哮喘的潜在机制方面取得了很大进展，但近几十年来，治疗这种疾病的药理工具相对较少。我们的实验室有一些新的发现：(1)3-氨基丁酸A亚型(GABAA)GABAA受体表达于气道平滑肌细胞上，(2)内源性GABAA能配体-受体系统存在于气道中，(3)激活内源性GABAA受体可增强松弛，(4)GABA(内源性存在于气道)具有调节气道平滑肌张力的功能，(5)全身应用GABAA受体激动剂可减轻激动剂诱导的气道收缩，(6)异丙酚的部分支气管松弛作用是由气道平滑肌上的GABAA受体介导的。由于针对GABAA受体的配体/激动剂的药理学特异性由GABAA亚基组成决定，选择性靶向特定的亚基限制在给定的组织中有望改善治疗。因此，我们的目标是阐明气道平滑肌GABAA受体亚单位组成在调节气道平滑肌张力中的重要性。我们先前已经证明，人的呼吸道平滑肌表达有限但高度保守的GABAA受体亚基(包括14、15、23、32和42)。这种有限的亚基谱系是有利的，因为它可以高度选择性地靶向表达在呼吸道平滑肌上的GABAA)受体。为这一提议产生的令人兴奋的初步数据支持了这样的中心假设，即呼吸道上皮是呼吸道GABA的重要细胞来源。它通过激酶调节的GABA转运体(GAT2和GAT4/BGT-1)从上皮细胞释放出来，作用于呼吸道平滑肌细胞上含有14和/或15个GABAA受体的受体，以促进松弛。这些发现提供了一种根本性的新疗法、一种转化性治疗方法和一种新的范式，即通过呼吸道上皮和平滑肌之间的旁分泌相互作用来缓解气道收缩。与公共卫生相关：这项研究要解决的中心假设是，呼吸道上皮是呼吸道GABA的细胞来源，通过激酶调节的GABA转运体(GAT2和GAT4/BGT-1)从上皮细胞释放GABA。这种释放的GABA可以作用于呼吸道平滑肌细胞上含有14和/或15个GABAA受体的受体，以促进松弛。我们计划确定14或15种新的亚基选择性激动剂，它们可以通过气雾剂输送到呼吸道，以促进呼吸道松弛。这些发现提供了一种根本性的新疗法、一种转化性治疗方法和一种新的范式，即通过呼吸道上皮和平滑肌之间的旁分泌相互作用来缓解气道收缩。